Cancer Care by Committee to be Superseded by Personal Physician–Patient Partnership Informed by Artificial Intelligence

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Multidisciplinary tumor boards (MTBs) have become the reference standard of cancer management, founded upon randomized controlled trial (RCT) evidence-based guidelines. The inordinate delays inherent in awaiting formal regulatory agency approvals of novel therapeutic agents, and the rigidities and nongeneralizability of this regimented approach, often deny cancer patients timely access to effective innovative treatment. Reluctance of MTBs to accept theranostic care of patients with advanced neuroendocrine tumors (NETs) and metastatic castrate-resistant prostate cancer resulted in decades of delay in the incorporation of 177Lu-octreotate and 177Lu-prostate-specific membrane antigen (PSMA) into routine clinical oncology practice. Recent developments in immunotherapy and molecular targeted precision therapy, based on N-of-One individual multifactorial genome analyses, have greatly increased the complexity of decision-making. Burgeoning specialist workload and tight time frames now threaten to overwhelm the logistically, and emotionally, demanding MTB system. It is hypothesized that the advent of advanced artificial intelligence technology and Chatbot natural language algorithms will shift the cancer care paradigm from a MTB management model toward a personal physician–patient shared-care partnership for real-world practice of precision individualized holistic oncology.

Original languageEnglish
Pages (from-to)497-505
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number8
Early online date27 Jun 2023
Publication statusPublished - 5 Oct 2023

Cite this